Nasdaq GlobeNewswire

Hemp, Inc. Reports: Sessions' Obsession about Marijuana Does Not Include Industrial Hemp and Definitely Not Kenaf

Del

SPRING HOPE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Hemp, Inc. (OTC PINK:HEMP) executives respond today to the U.S. Attorney General Jeff Sessions' decision to rescind the Cole memo that ignited a marijuana stock sell-off.  However, Sessions' stance on cannabis does NOT include industrial hemp and it definitely does NOT include kenaf, says Bruce Perlowin, CEO of Hemp, Inc. With 18,000,000 pounds of kenaf in inventory and another, approximate, 2,000,000 pounds of kenaf to be harvested early this year, Hemp, Inc. executives are not the least bit worried about their supply chain or if there will be any marijuana pushback by the federal government.

"Investors in Hemp, Inc. have nothing to worry about or fear," says Perlowin. Hemp, Inc., as reported in a press release yesterday, is processing its first two purchase orders. a truckload of kenaf fiber and a truckload of its kenaf loss circulation material (LCM). "This was not two truckloads of recreational marijuana. This was not two truckloads of medical marijuana. This was not even two truckloads of industrial hemp. It was one truckload of kenaf LCMs that's going to Texas and one truckload of kenaf fiber that's going to New Jersey. So no matter how Sessions marijuana obsession plays out, Hemp, Inc. is a safe bet for anyone concerned or hesitant about this new development," said Perlowin. As a global leader in the industrial hemp industry, with the largest multi-purpose industrial hemp processing facility in the western hemisphere, Hemp, Inc. is as sure of an investment as it was before Sessions' unpopular new war on the marijuana industry was announced.

This opinion is shared by many others in the industrial hemp industry. Whole Foods Magazine published an articleWhat Sessions Move on Marijuana Means for Hemp, CBD, and it says Sessions' decision should not affect businesses that are hemp-based. Sessions rescinding the Cole memo applies to marijuana related companies, not hemp companies. Read the full article here.

According to the article published in the RollingStone, Jeff Sessions' unpopular decision brought "swift condemnation from both Republicans and Democrats" alike, with National Republican Senatorial Committee head, Senator Cory Gardner blasting Sessions as "a liar." To read the full press release, click here.

CONTACT INFORMATION

Hemp, Inc.
(855) HEMP-OUT
info@hempinc.com
http://www.hempinc.com

For Investor Relations, please send correspondence to: ir@hempinc.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hemp, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21Pressemelding

BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad

Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer18.10.2018 14:03Pressemelding

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer. As a result, former Chief Medical Officer Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. The Company also announced the appointment of Neena Patil, J.D. as General Counsel and Corporate Secretary. Both Dr. Siffert and Ms. Patil report to Chief Executive Officer, Carsten Thiel, Ph.D. “I am very pleased to welcome João and Neena to Abeona, and confident in their abilities to make important contributions to the future growth of our company,” said Dr. Thiel. “João has an ideal blend of clinical, scientific, and regulatory experience to reference as we look to advance our clinical and pre-clinical can

Meltwater and Dow Jones Announce Global Partnership to Provide Premium Content18.10.2018 14:00Pressemelding

SAN FRANCISCO and NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media intelligence, today announces the launch of a partnership with Dow Jones, a global provider of news and business information, to provide premium licensed content from Dow Jones Factiva into the Meltwater Media Intelligence platform. This partnership will give Meltwater’s PR and communications clients the ability to monitor and analyze premium licensed content across thousands of Factiva news sources globally, including: The Wall Street Journal, America’s largest newspaper by paid circulation; Barron’s; MarketWatch; and Dow Jones Newswires. “Meltwater provides our clients with the most comprehensive content network globally, across news, social media and broadcast media. This new Dow Jones partnership will further strengthen our leadership position and allow our clients to access licensed content from some of the most highly-respected news outlets in the world. We’re excited about this part

Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting18.10.2018 13:30Pressemelding

EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. Data to be presented across the Alzheimer’s disease clinical development portfolio, including aducanumab, BAN2401 and elenbecestat CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27). The data being presented are part of Biogen’s ongoing research programs targeting possible causes of the disease through multiple modalities. “We are excited to engage with the scientific community at CTAD, to share learnings from our Alzheimer’s disease clinical research and to learn from the work of our colleagues around the world. We have hopes that our

SEMAFO Provides Notice of Third Quarter 2018 Results Release and Conference Call   18.10.2018 13:30Pressemelding

MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX, OMX: SMF) invites you to participate in a conference call on November 7, 2018 at 10:00 AM EST with senior management during which they will review the Corporation's third quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the third quarter 2018 will be released on November 6 after market hours and will be available in the “Investor Relations” section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO’s website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 2823689 Expiration: December 7, 2018 About SEMAFO SEMAFO is a Canadian-b

Biome Grow Announces Listing on the Frankfurt Stock Exchange under symbol 60TA18.10.2018 13:30Pressemelding

TORONTO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- (CSE: BIO) – Biome Grow (“Biome” or the “Company”) (CSE:BIO) is pleased to announce that the Company’s common shares have been listed on the Frankfurt Stock Exchange under the trading symbol “6OTA”. The Company’s common shares continue to be listed on the Canadian Securities Exchange (“CSE”) under the trading symbol “BIO”. “Biome is developing its production base in Canada with an eye to becoming a leader in the international medical cannabis market. Listing on the Frankfurt Stock Exchange will give Biome increased access to European and other international investors and positions Biome well for international growth and development opportunities,” said CEO Khurram Malik. The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom